Cravath’s London Office Moves to 100 Cheapside
On November 23, 2022, Cravath partner David J. Kappos participated in the 2022 International Mediation Summit, which was hosted by the China Council for the Promotion of International Trade Mediation Center and Xiamen Municipal People’s Government. Dave delivered a presentation which reviewed the importance of mediation and alternative dispute resolution (“ADR”) in the intellectual property space and what will be needed for China to establish a credible presence in intellectual property ADR.
Deals & Cases
November 07, 2022
On November 7, 2022, Viatris Inc. (“Viatris”), a global healthcare company, announced it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma (“Oyster Point”) and Famy Life Sciences.
Deals & Cases
October 11, 2022
On October 11, 2022, Brookfield Renewable Partners (“Brookfield Renewable”), together with its institutional partners and Cameco Corporation (“Cameco”), announced they are forming a strategic partnership (“the consortium”) to acquire Westinghouse Electric Company (“Westinghouse”), one of the world’s largest nuclear services businesses, for a total enterprise value of $7.875 billion.
Deals & Cases
August 08, 2022
On August 8, 2022, Global Blood Therapeutics, Inc. (“GBT”), a biopharmaceutical company dedicated to the discovery, development and delivery of life‑changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (“Pfizer”) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. Cravath is representing GBT in connection with the transaction.
Deals & Cases
June 21, 2022
On June 21, 2022, Convey Health Solutions Holdings, Inc. (“Convey”), a leading healthcare technology and services company, announced that it has entered into a definitive merger agreement pursuant to which TPG Capital, the private equity platform of global alternative asset management firm TPG and Convey’s principal shareholder, will acquire all of the outstanding shares of Convey common stock not currently owned by TPG or certain management and director shareholders for $10.50 per share in cash, representing an enterprise value of approximately $1.1 billion. Cravath is representing Convey in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.